581 Topical calcipotriol plus imiquimod immunotherapy for non-keratinocyte skin cancers

Non-keratinocyte cutaneous malignancies including breast cancer cutaneous metastasis and melanoma in situ are often poor surgical candidates due to their anatomical location, size and the morbidities associated with surgery. Imiquimod, a toll-like receptor 7 agonist, is used for the treatment of these cutaneous malignancies, which activates the innate immunity in the skin. However, imiquimod ’s modest effect on the activation of adaptive immunity limits its efficacy as a monotherapy. We have previously demonstrated that topical induction of thymic stromal lymphopoietin (TSLP) cytokine by calcipotriol protects against skin and breast cancer development by directly activating T cell imm unity.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Source Type: research